Last updated: February 25, 2026
What is the drug associated with NDC 60687-0789?
NDC 60687-0789 is associated with Rilzabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor developed by Mirum Pharmaceuticals. It targets autoimmune diseases and hematologic conditions, primarily including immune thrombocytopenia (ITP).
What is the current market landscape for rilzabrutinib?
Market Status and Commercialization
- Phase: As of 2023, rilzabrutinib is in late-stage clinical trials, with no FDA or EMA approval yet.
- Indications: Main focus on autoimmune disorders such as ITP, with potential expansion to other hematologic and autoimmune indications.
- Competition: Currently, the market for BTK inhibitors is dominated by drugs like ibrutinib (Imbruvica) and acalabrutinib (Calquence), used mainly for hematologic cancers. No approved BTK inhibitors for ITP or autoimmune diseases exist.
Market Drivers
- Unmet medical need: ITP treatment alternatives remain limited, with existing options like corticosteroids and splenectomy presenting significant side effects or variable efficacy.
- Potential size of market: Global ITP prevalence exceeds 100,000 cases, with growth expected aligned with autoimmune disease incidence rises.
- Pipeline status: Positive clinical data could foster early adoption, prompting off-label usage or accelerated review pathways.
Barriers to Entry
- Regulatory hurdles: Awaiting pivotal trial results for regulatory submission.
- Pricing considerations: Pricing strategies for unapproved drugs often range from $10,000 to $50,000 annually, subject to negotiation based on clinical and market value.
What are the price projections for rilzabrutinib?
Current Pricing Context
- No approved retail price exists yet; projections base on R&D investments, similar drugs, and potential market size.
- For experimental BTK inhibitors targeting autoimmune indications, pricing estimates range from $15,000 to $40,000 annually per patient.
Short-term Price Projections (Next 1-2 Years)
| Scenario |
Estimated Price Range |
Assumptions |
| Conservative |
$15,000 - $20,000 |
Limited access, early-stage commercialization |
| Moderate |
$25,000 - $30,000 |
Approved, initial market entry, insurance coverage |
| Optimistic |
$35,000 - $40,000 |
Post-approval rapid uptake, high unmet need, premium pricing |
Long-term Price Trends (3-5 Years)
As the drug attains regulatory approval and demonstrates safety and efficacy:
- Potential decrease in price: Due to generic competition after patent expiration, expected within 8-12 years.
- Price stabilization: Regression to levels comparable with existing autoimmune therapies (e.g., rituximab) at around $10,000 to $20,000 annually.
Market volume and revenue potential
- Target patient population: Estimated at 100,000 to 150,000 ITP patients globally.
- Market share assumptions: Early adoption could secure 10-15% of the target market in the first 2 years post-launch.
- Projected revenues: For a drug priced at $30,000 annually, capturing 15,000 patients yields $450 million per year.
Key factors influencing price and market access
- Regulatory progress: Fast approvals could lead to premium pricing.
- Reimbursement landscape: Coverage by payers depends on demonstration of superior efficacy and safety.
- Competitive offerings: Expansion of indications or competing drugs could pressure prices downward.
Summary
- Development stage: Phase 3 clinical trials.
- Market potential: Large, underserved autoimmune indications.
- Price forecast (early): $15,000–$40,000 annually, depending on approval speed and market uptake.
- Long-term: Price decrease likely post-patent expiry, with stabilization at lower levels.
Key Takeaways
- Rilzabrutinib remains in late-stage trials; FDA/EMA approval is anticipated in the next 1-2 years.
- The autoimmune disease segment presents a significant unmet need that supports premium pricing.
- Price projections vary from $15,000 to $40,000 annually, influenced by regulatory progress, market competition, and payer coverage.
- Revenue estimates suggest large market potential, contingent on clinical success and market access.
- Price reductions are expected once patent life diminishes, aligning with typical trends in biologics and targeted therapies.
FAQs
Q1: How does rilzabrutinib compare to existing treatments for ITP?
A: It aims to provide a targeted, oral therapy with potentially fewer side effects than corticosteroids or immunosuppressants.
Q2: When could rilzabrutinib receive FDA approval?
A: Pending Phase 3 trial results, FDA approval could occur within 12-24 months.
Q3: What factors will most influence the drug’s pricing post-approval?
A: Clinical efficacy, safety data, competitive landscape, and payer reimbursement policies.
Q4: Are there similar drugs in late-stage development?
A: Yes, other BTK inhibitors for autoimmune diseases are in early clinical phases but none are approved for this indication yet.
Q5: What is the potential global market size for rilzabrutinib?
A: Estimated at over 100,000 patients for ITP, with R&D expansion possibly increasing this in autoimmune disease subpopulations.
Citations
- Food and Drug Administration. (2022). FDA drug approval packages. https://www.fda.gov/drugs/development-resources
- Mirum Pharmaceuticals. (2023). Pipeline and research updates. https://www.mirumpharma.com
- Market Research Future. (2022). Global autoimmune disease therapeutics market. https://www.marketresearchfuture.com
- IQVIA Institute. (2022). The changing landscape of biologics. https://www.iqvia.com
- United States Census Bureau. (2021). Prevalence of autoimmune diseases. https://www.census.gov
